Heparan sulfate proteoglycans (HSPGs) are cell surface receptors that are involved in the cellular uptake of pathologic amyloid proteins and viruses, including the novel coronavirus; severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Heparin and heparan sulfate antagonize the binding of these pathogens to HSPGs and stop their cellular internalization, but the anticoagulant effect of these agents has been limiting their use in the treatment of viral infections. Heparin-binding peptides (HBPs) are suitable nonanticoagulant agents that are capable of antagonizing binding of heparin-binding pathogens to HSPGs. Here, we review and discuss the use of HBPs as viral uptake inhibitors and will address their benefits and limitations to treat viral infections. Furthermore, we will discuss a variant of these peptides that is in the clinic and can be considered as a novel therapy in coronavirus disease 2019 (COVID-19) infection.

中文翻译：

---

肝素结合肽作为阻止SARS-CoV-2细胞进入和感染的新疗法。

硫酸乙酰肝素蛋白聚糖（HSPG）是细胞表面受体，参与病理性淀粉样蛋白和病毒（包括新型冠状病毒）的细胞摄取。严重急性呼吸系统综合症冠状病毒2（SARS-CoV-2）。肝素和硫酸乙酰肝素拮抗这些病原体与HSPG的结合并停止其细胞内在化，但是这些药物的抗凝作用一直限制了它们在治疗病毒感染中的用途。肝素结合肽（HBP）是合适的非抗凝剂，其能够拮抗肝素结合病原体与HSPG的结合。在这里，我们审查和讨论HBPs作为病毒摄取抑制剂的用途，并将解决其治疗病毒感染的益处和局限性。此外，